ORIC Pharmaceuticals, Inc.
HealthcareNASDAQ:ORIC · NASDAQ Global Select
+$0.45 today
Vol 1.56M · Avg 1.89M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.7%
avg -34.3%
ROIC
-36.3%
avg -44.1%
ROA
-31.5%
avg -39.1%
Analysis
ROA is currently the strongest return metric at -31.5% versus its period average of -39.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jacob Chacko | President, Chief Executive Officer & Director | $1.11M | — | 47 | $675,000.00 | 0.65% |
Pratik S. Multani | Chief Medical Officer | $774,937.00 | — | 59 | $214,000.00 | 0.21% |
Dominic G. Piscitelli | Chief Financial Officer | $729,921.00 | — | 51 | $144,500.00 | 0.14% |
Richard A. Heyman | Founder, Independent Chairman & Member of Scientific Advisory Board | $100,000.00 | — | 69 | $41,800.00 | 0.04% |
Christian V. Kuhlen | General Counsel | — | — | 53 | — | — |
Kevin Brodbeck | Chief Technical Officer | — | — | — | — | — |
Matthew Panuwat | Chief Business Officer | — | — | 48 | — | — |
Edna Chow Maneval | Executive Vice President of Clinical Development | — | — | 65 | — | — |
Scott W. Lowe | Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Daniel Iazzetti | Vice President & Head of People | — | — | — | — | — |
Charles L. Sawyers | Founder & Member of Scientific Advisory Board | — | — | 67 | $40,000.00 | 0.04% |
Lori Sickels Friedman | Chief Scientific Officer | — | — | 61 | $40,000.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$262,898.99
Sells
15
$4.86M
Net Sentiment
$4.59M
Net selling
Most Active
Piscitelli Dominic
7 transactions
1–10 of 17
Analysis
Insiders reported 2 buys worth $262,898.99 and 15 sells worth $4.86M over the last 12 months. That adds up to net selling of $4.59M. Piscitelli Dominic was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
Tourmaline Bio, Inc.
TRML
$1.23B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Who manages ORIC?
ORIC Pharmaceuticals, Inc. (ORIC) lists 12 active executives. The top listed executive is Christian V. Kuhlen, General Counsel.
Are ORIC insiders buying or selling?
Recent insider activity shows net buying of $18.43M.
Explore More
Continue the stock analysis
Jump to another research area for this company.